Cost-effectiveness of community-acquired pneumonia therapy

Abstract

Community-acquired pneumonia is a common disease in adults and substantially contributes to morbidity and mortality in the USA and worldwide. Due to the significant costs associated with this disease, there is increasing pressure to evaluate the variation in practices among healthcare providers. The processes of care related to the diagnosis, management and prevention of community-acquired pneumonia are reviewed. Furthermore, the cost-effective strategies for community-acquired pneumonia and the medical evidence that support their usage are outlined.

• antimicrobial
• azithromycin
• ceftriaxone
• cost
• cost-effective
• flouroquinolone
• guidelines
• length of stay
• levofloxacin
• macrolide
• mortality
• pneumonia